Post-earnings recap
Reported
Thu, Apr 30, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss of $0.44 per share, which was worse than expected. The stock reacted negatively, declining by 3.95%. The lack of revenue and guidance may raise concerns among investors about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.44 | N/A | -11.39% |
| Revenue | $0 | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.